Back to Search
ALLEN GOWN, MD
MD
Specialist
NPI: 1689779134Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MD00017132(WA)
Research & Publications (20)
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
PMID 18487992·Mod Pathol·2008
4-observational
Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3.
PMID 11897797·J Histochem Cytochem·2002
8-other
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry.
PMID 19363444·Appl Immunohistochem Mol Morphol·2009
8-other
Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis.
PMID 19587802·PLoS One·2009
8-other
Anaplastic thyroid carcinoma exhibits intratumoral molecular homogeneity for a therapeutic target panel.
PMID 19596911·Anticancer Res·2009
8-other
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
PMID 19620488·J Clin Oncol·2009
8-other
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.
PMID 18941404·Am J Surg Pathol·2009
8-other
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
PMID 19653732·Arch Pathol Lab Med·2009
6-review
Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
PMID 18612701·Ann Surg Oncol·2008
8-other
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
PMID 18199553·Cancer Res·2008
7-preclinical
Biomarker panel diagnosis of thyroid cancer: a critical review.
PMID 18759692·Expert Rev Anticancer Ther·2008
6-review
Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
PMID 18424286·Am J Surg·2008
8-other
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
PMID 19073506·Clin Breast Cancer·2008
3-trial
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
PMID 19001334·J Clin Oncol·2008
8-other
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
PMID 17912629·Breast Cancer Res Treat·2008
8-other
HER2 in well differentiated breast cancer: is testing necessary?
PMID 18202913·Breast Cancer Res Treat·2008
4-observational
Clinical utility of type 1 growth factor receptor expression in colon cancer.
PMID 18424279·Am J Surg·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 551 N 34TH ST STE 100
SEATTLE, WA 98103 - Phone
- (206) 374-9000
Quick Facts
- NPI
- 1689779134
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile